Status:
TERMINATED
A Study of Cytotoxic T Lymphocyte (CTL) Therapy in HIV-Infected Patients
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
HIV Infections
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
To define the safety of cytotoxic T lymphocytes (CTLs) generated from sibling-supplied dendritic cells and lymphocytes and infused into an HIV-infected patient. To determine the efficacy of these CTLs...
Detailed Description
With lower CD4 counts, HIV-infected patients may not be able to produce dendritic cells and lymphocytes, special types of immune cells that generate HIV-specific CTLs. Infusion of CTLs generated from ...
Eligibility Criteria
Inclusion Criteria
Patients must have:
- HLA A2+.
- Other HLA matching with sibling.
- CD4 count 100-350 cells/mm3.
- No active opportunistic infection or malignancy (other than cutaneous Kaposi's sarcoma).
- Current stable antiviral regimen.
- Normal lab values and chest x-ray.
Donor siblings must have:
- HLA A2+.
- HIV negativity.
- Good venous access.
- Ability to donate on multiple occasions.
- Negative status for hepatitis B and C.
Exclusion Criteria
Concurrent Medication:
Excluded:
- Immunomodulators.
- Cytokines.
- Systemic steroids.
- IV pentamidine.
- Investigational drugs.
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
June 1 2005
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00000824
End Date
June 1 2005
Last Update
December 14 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford Univ School of Medicine
Stanford, California, United States, 943055107